Calcium Silicate

Summary

Calcium Silicate (CHEMBL2108942) is a phase-3 clinical-stage unknown (ATC A02AC02).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A02AC02
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108942
Name	Calcium Silicate
Type	Unknown
Max phase	3
ATC	A02AC02

Also known as: Calcarea silicata, Calcium silicate, E-552, Huberderm 1000, INS NO.552, INS-552, Silicic acid, calcium salt, CALCIUM SILICATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03032978	Not specified	COMPLETED	Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment
NCT06307678	Not specified	COMPLETED	Effect of Calcium Silicate Based Root Canal Medicament on Inflammatory Mediators
NCT06779370	Not specified	COMPLETED	Effect of Calcium Silicate-Based Root Canal Medicament After Retreatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).